Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress
Lucid Diagnostics (Nasdaq: LUCD) announced its participation as the sole Diamond Sponsor at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress in Edinburgh, Scotland, from September 22-24, 2024. The company will showcase its EsoGuard® Esophageal DNA Test for early detection of esophageal precancer.
Lucid will host a symposium on Non-Endoscopic Screening for Barrett's Esophagus, chaired by experts Dr. Vani Konda and Dr. Nicholas Shaheen. The panel discussion will include Dr. Vivek Kaul and Dr. Rehan Haidry. This event highlights Lucid's commitment to being a leading voice in esophageal cancer prevention through early detection of precancer.
The ISDE World Congress is a global platform for collaboration and knowledge exchange among experts in esophageal diseases, covering topics such as diagnostics, novel therapies, and latest advancements in the field.
Lucid Diagnostics (Nasdaq: LUCD) ha annunciato la sua partecipazione come unico Diamond Sponsor al 20º Congresso Mondiale della Società Internazionale per le Malattie dell'Esofago (ISDE) che si terrà a Edimburgo, Scozia, dal 22 al 24 settembre 2024. L'azienda presenterà il suo EsoGuard® Esophageal DNA Test per la rilevazione precoce dei precursori del cancro esofageo.
Lucid ospiterà un simposio su Screening Non Endoscopico per l'Esofago di Barrett, presieduto dagli esperti Dr. Vani Konda e Dr. Nicholas Shaheen. La tavola rotonda includerà il Dr. Vivek Kaul e il Dr. Rehan Haidry. Questo evento mette in evidenza l'impegno di Lucid a essere una voce di riferimento nella prevenzione del cancro esofageo attraverso la rilevazione precoce dei precursori.
Il Congresso Mondiale ISDE è una piattaforma globale per la collaborazione e lo scambio di conoscenze tra esperti in malattie esofagee, trattando argomenti come la diagnostica, terapie innovative e gli ultimi sviluppi nel campo.
Lucid Diagnostics (Nasdaq: LUCD) anunció su participación como el único patrocinador Diamante en el 20º Congreso Mundial de la Sociedad Internacional de Enfermedades del Esófago (ISDE), que se llevará a cabo en Edimburgo, Escocia, del 22 al 24 de septiembre de 2024. La empresa presentará su EsoGuard® Esophageal DNA Test para la detección temprana de precáncer esofágico.
Lucid organizará un simposio sobre Screening No Endoscópico para el Esófago de Barrett, presidido por los expertos Dr. Vani Konda y Dr. Nicholas Shaheen. La mesa redonda incluirá al Dr. Vivek Kaul y al Dr. Rehan Haidry. Este evento destaca el compromiso de Lucid de ser una voz líder en la prevención del cáncer esofágico a través de la detección temprana de precáncer.
El Congreso Mundial ISDE es una plataforma global para la colaboración y el intercambio de conocimientos entre expertos en enfermedades esofágicas, abarcando temas como diagnósticos, nuevas terapias y los últimos avances en el campo.
루시드 진단 (Nasdaq: LUCD)은 2024년 9월 22일부터 24일까지 스코틀랜드 에든버러에서 열리는 제20회 국제 식도 질환 학회(ISDE) 세계 총회에 독점 다이아몬드 후원사로 참여한다고 발표했습니다. 이 회사는 식도 전암의 조기 발견을 위한 EsoGuard® 식도 DNA 검사를 선보일 예정입니다.
루시드는 전문가인 Dr. Vani Konda와 Dr. Nicholas Shaheen이 주재하는 바렛 식도 비내시경 스크리닝에 관한 심포지엄을 개최합니다. 패널 토론에는 Dr. Vivek Kaul과 Dr. Rehan Haidry가 포함됩니다. 이 행사는 조기 발견을 통한 식도암 예방에서 루시드의 선도적인 목소리가 되고자 하는 의지를 강조합니다.
ISDE 세계 총회는 진단, 새로운 치료법, 가장 최근의 발전 등 식도 질환에 관한 전문가들 간의 협력과 지식 교환을 위한 글로벌 플랫폼입니다.
Lucid Diagnostics (Nasdaq: LUCD) a annoncé sa participation en tant que seul sponsor Diamant au 20ème Congrès Mondial de la Société Internationale des Maladies de l'Oesophage (ISDE), qui se déroulera à Édimbourg, en Écosse, du 22 au 24 septembre 2024. L'entreprise présentera son EsoGuard® Test ADN de l'oesophage pour la détection précoce des lésions précoces du cancer de l'œsophage.
Lucid animera un symposium sur le Dépistage Non-Endoscopique pour l'Oesophage de Barrett, présidé par les experts Dr. Vani Konda et Dr. Nicholas Shaheen. La discussion en panel inclura Dr. Vivek Kaul et Dr. Rehan Haidry. Cet événement met en lumière l'engagement de Lucid à être une voix parmi les leaders dans la prévention du cancer de l'œsophage grâce à la détection précoce des lésions précoces.
Le Congrès Mondial de l'ISDE est une plateforme mondiale pour la collaboration et l'échange de connaissances entre experts en maladies de l'œsophage, couvrant des sujets tels que le diagnostic, les nouvelles thérapies et les dernières avancées dans le domaine.
Lucid Diagnostics (Nasdaq: LUCD) gab bekannt, dass es als alleiniger Diamant-Sponsor am 20. Internationalen Kongress der Gesellschaft für Erkrankungen der Speiseröhre (ISDE) teilnehmen wird, der vom 22. bis 24. September 2024 in Edinburgh, Schottland, stattfindet. Das Unternehmen wird seinen EsoGuard® Speiseröhren-DNA-Test zur frühzeitigen Erkennung von Speiseröhren-Vorläuferkrebs präsentieren.
Lucid veranstaltet ein Symposium zum Thema Nicht-endoskopisches Screening für den Barrett-Essophagus, geleitet von den Experten Dr. Vani Konda und Dr. Nicholas Shaheen. In der Podiumsdiskussion nehmen Dr. Vivek Kaul und Dr. Rehan Haidry teil. Diese Veranstaltung unterstreicht Lucids Engagement, eine führende Stimme in der Prävention von Speiseröhrenkrebs durch frühzeitige Erkennung von Vorläuferkrebs zu sein.
Der ISDE-Weltkongress ist eine globale Plattform für Zusammenarbeit und Wissensaustausch unter Experten für Speiseröhrenerkrankungen und behandelt Themen wie Diagnostik, neuartige Therapien und die neuesten Fortschritte auf diesem Gebiet.
- None.
- None.
Leading experts to discuss advances in technologies to prevent esophageal cancer through esophageal precancer screening
Lucid will also host a symposium entitled Non-Endoscopic Screening for Barrett's Esophagus chaired by distinguished experts in esophageal diseases, including Vani Konda, M.D., Medical Director of the Center for Esophageal Diseases at Baylor Scott & White Health, and Nicholas Shaheen, M.D., M.P.H., Professor and Chief of Gastroenterology & Hepatology at UNC Chapel Hill, the current ISDE President and lead author of the American College of Gastroenterology (ACG) guidelines on esophageal precancer screening. The symposium's panel discussion will include Vivek Kaul, M.D., Professor in the Division of Gastroenterology & Hepatology at the University of Rochester Medical Center, and Rehan Haidry, M.D., Consultant Gastroenterologist at Cleveland Clinic London.
"At Lucid, we are committed to be the leading international voice on esophageal cancer prevention though early detection of esophageal precancer and are excited to have a strong presence at this year's ISDE World Congress, a premier global event for international experts in esophageal disease," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "We are particularly excited to host our first international symposium on non-endoscopic esophageal precancer screening led by renowned specialists from
The ISDE World Congress is a premier global conference that brings together experts from various specialties involved in the clinical management and research of esophageal diseases. The event provides a valuable platform for collaboration and knowledge exchange among leading experts in esophageal diseases. This year's congress will cover a wide range of topics, including diagnostics, novel therapies, and the latest advancements impacting the field of esophageal diseases.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-host-symposium-on-non-endoscopic-esophageal-precancer-screening-at-the-20th-international-society-for-diseases-of-the-esophagus-isde-world-congress-302243469.html
SOURCE Lucid Diagnostics
FAQ
When and where is Lucid Diagnostics (LUCD) participating in the ISDE World Congress?
What is Lucid Diagnostics (LUCD) showcasing at the ISDE World Congress?
Who are the experts chairing Lucid Diagnostics' (LUCD) symposium at the ISDE World Congress?
What is the title of Lucid Diagnostics' (LUCD) symposium at the ISDE World Congress?
What is Lucid Diagnostics' (LUCD) sponsorship level at the ISDE World Congress?
